VIMGF (Vimian Group AB) ROC (Joel Greenblatt) %: 98.36% (As of Mar. 2026) — 41% Above Median


VIMGF Vimian Group AB VIMGF
69 GF Score
Price $2.77
GF Value $3.19
! 2 Warning Signs
View Full Analysis

What is Vimian Group AB ROC (Joel Greenblatt) %?

Vimian Group AB VIMGF 69 ROC (Joel Greenblatt) % is 98.36% as of Mar. 2026, which is 41% above its 10-year median of 69.62. GuruFocus rates VIMGF with a GF Score™ of 69/100 and a GF Value™ of $3.19. The stock has 2 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Vimian Group AB ranks better than 93.43% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Vimian Group AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 98.36%.

The historical rank and industry rank for Vimian Group AB's ROC (Joel Greenblatt) % or its related term are showing as below:

VIMGF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -46.37   Med: 69.62   Max: 549.78
Current: 83.16

During the past 9 years, Vimian Group AB's highest ROC (Joel Greenblatt) % was 549.78%. The lowest was -46.37%. And the median was 69.62%.

VIMGF's ROC (Joel Greenblatt) % is ranked better than
93.43% of 213 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.02 vs VIMGF: 83.16

Vimian Group AB's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -24.10% per year.


Vimian Group AB  (OTCPK:VIMGF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Vimian Group AB ROC (Joel Greenblatt) % Related Terms


Vimian Group AB ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Vimian Group AB's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vimian Group AB ROC (Joel Greenblatt) % Chart

Vimian Group AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only 76.85 34.46 70.36 66.89 82.73

Vimian Group AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.90 71.04 73.51 84.41 98.36

VIMGF vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison

For the Diagnostics & Research subindustry, Vimian Group AB's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vimian Group AB ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Vimian Group AB's ROC (Joel Greenblatt) % falls into.


VIMGF
69GF Score
Vimian Group AB VIMGF
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vimian Group AB ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(67.096 + 93.794 + 8.196) - (34.895 + 0 + 87.236)
=46.955

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(75.376 + 101.503 + 3.122) - (45.434 + 0 + 99.653)
=34.914

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Vimian Group AB for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=97.572/( ( (54.45 + max(46.955, 0)) + (62.081 + max(34.914, 0)) )/ 2 )
=97.572/( ( 101.405 + 96.995 )/ 2 )
=97.572/99.2
=98.36 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 98.36% mean?
Vimian Group AB (VIMGF) has a ROC (Joel Greenblatt) % of 98.36% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vimian Group AB and its competitors. This is 41% above median its historical median of 69.62. According to the industry distribution chart, Vimian Group AB ranks #14 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 6.6%.
Is Vimian Group AB's ROC (Joel Greenblatt) % too high?
Vimian Group AB's current ROC (Joel Greenblatt) % of 98.36% is 41% above median its 10-year median of 69.62. Based on the distribution chart, Vimian Group AB ranks #14 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Vimian Group AB has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #14 out of 213 companies for ROC (Joel Greenblatt) %. This places Vimian Group AB in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vimian Group AB and its competitors. Vimian Group AB's current ROC (Joel Greenblatt) % is 98.36%, which is 41% above median its own 10-year median of 69.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Vimian Group AB (VIMGF) has a current ROC (Joel Greenblatt) % of 98.36%. The stock's GF Value™ is $3.19, compared to a current price of $2.77 — trading 13.2% below its estimated fair value. The current ROC (Joel Greenblatt) % is 98.36%, which is 41% above median its 10-year median of 69.62. Vimian Group AB's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Vimian Group AB (VIMGF), the current ROC (Joel Greenblatt) % is 98.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vimian Group AB (VIMGF) Overvalued in 2026?

Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued. The current stock price of $2.77 is trading 13.2% below its estimated GF Value™ of $3.19.

Key valuation signals for VIMGF:

  • ROC (Joel Greenblatt) %: 98.36% (41% above median its 10-year median of 69.62)
  • GF Value™: $3.19 vs. price of $2.77 (13.2% below fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the VIMGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vimian Group AB Business Description

Address Riddargatan 19, Stockholm, SWE, SE-11457
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
69GF Score

Get the complete analysis for VIMGF

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.77
Price
$3.19
GF Value